Skip to main content
. 2024 Apr 19;5(5):101518. doi: 10.1016/j.xcrm.2024.101518

Table 2.

Clinical diagnosis and phenotypes for 644 observations of pathogenic/likely pathogenic or loss-of-function (P/LP/LoF) variants in 614 individuals

Disease Genes Variants Observations, n +Dx, n (% of observations) −Dx -Sx, n (% of −Dx observations) −Dx +Sx, n (% of −Dx observations)
Amyotrophic lateral sclerosis 4 19 21 1 (4.8) 15 (80) 5 (20)
Cardiomyopathy 21 151 234 80 (34) 124 (81) 30 (19)
Colorectal cancer 7 16 19 2 (11) 15 (88) 2 (12)
Endometrial cancer 1 1 13 1 (7.7) 8 (67) 4 (33)
Familial breast cancer 4 64 168 62 (37) 83 (78) 23 (22)
Familial hypercholesterolemia 1 7 11 5 (45) 3 (50) 3 (50)
Monogenic diabetes 1 1 1 1 (100)
Prostate cancer 1 2 2 2 (100)
Retinitis pigmentosa 15 42 175 3 (1.7) 164 (95) 8 (4.7)

A total of 644 observations of 303 pathogenic/likely pathogenic or predicted LoF (P/LP/LoF) variants carried by 614 individuals were identified for nine diseases. Observations were first categorized by whether the disease corresponding to the variant was clinically diagnosed (+Dx) or not clinically diagnosed (−Dx) in the individual with the variant. Electronic health records (EHRs) of clinically undiagnosed individuals were then evaluated and categorized by whether evidence of symptomatic disease was present (+Sx) or absent (−Sx). This resulted in three distinct groups: (1) clinically diagnosed (+Dx), (2) no clinical diagnosis and no EHR evidence of disease (−Dx −Sx), and (3) no clinical diagnosis but EHR evidence of disease (−Dx +Sx). n (% of observations), number and percentage of the observations of individuals with P/LP/LoF variants; n (% of −Dx observations), number and percentage of the observations of individuals with P/LP/LoF variants lacking a clinical diagnosis. Genes, number of disease predisposition genes containing the P/LP/LoF variants; Variants, number of P/LP/LoF variants; –, not applicable, as all observations for monogenic diabetes and prostate cancer were diagnosed with the corresponding disease.